Douglas Grossman, MD, Ph.D., co-leader of the Melanoma Center at Huntsman Cancer Institute at the University of Utah (the U) ...
A novel quantitative PET- and MRI-based imaging approach can objectively identify a recently recognized type of ...
A new molecular imaging agent can accurately identify a crucial biomarker found among many different types of cancer. Precise visualization of the trophoblast cell surface antigen 2 (Trop2) biomarker ...
Radiopharmaceutical therapy and molecular imaging—together known as Theranostics—are gaining significant traction worldwide. Even though Theranostics dates back to the early 1940s, a rapid expansion ...
Transitioning molecular imaging from a preclinical technique to a standard clinical tool could help detect the very earliest stages of disease, reports Tami Freeman Tools of the trade Left: this ...
Flourish Research ® today announced a strategic partnership with Capitol Imaging Services in advance of the launch of Flourish Imaging™, an advanced imaging center currently under development in ...
Novel approaches in molecular imaging and targeted therapeutics are transforming the management of renal cell carcinoma (RCC) and urothelial carcinoma (UC). This review focuses on three key areas of ...
BERLIN & NAPLES, Fla.--(BUSINESS WIRE)--Bayer, a leading company in key areas of radiology and cardiology, and Attralus, Inc. (Attralus), a clinical stage biopharmaceutical company focused on ...
A novel quantitative PET- and MRI-based imaging approach can objectively identify a recently recognized type of dementia--limbic-predominant age-related TDP-43 encephalopathy, or LATE--that is often ...
Bioluminescence imaging (BLI) has emerged as a transformative technique that facilitates non‐invasive, real‐time observation of molecular and cellular processes. By utilising luciferase enzymes in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results